Antifungal drugs during pregnancy: an updated review - Institut Pasteur Access content directly
Journal Articles Journal of Antimicrobial Chemotherapy Year : 2014

Antifungal drugs during pregnancy: an updated review


Antifungal prescription remains a challenge in pregnant women because of uncertainties regarding fetal toxicity and altered maternal pharmacokinetic parameters that may affect efficacy or increase maternal and fetal toxicity. We present updated data reviewing the available knowledge and current recommendations regarding antifungal prescription in pregnancy. Amphotericin B remains the first-choice parenteral drug in spite of its well-established toxicity. Topical drugs are used throughout pregnancy because of limited absorption. Recent data have clarified the teratogenic effect of high-dose fluconazole during the first trimester and provided reassuring cumulative data regarding its use at a single low dose in this key period. Recent data have also provided additional safety data on itraconazole and lipidic derivatives of amphotericin B. Regarding newer antifungal drugs, including posaconazole and echinocandins, clinical data are critically needed before considering prescription in pregnancy.

Dates and versions

pasteur-02454062 , version 1 (24-01-2020)



Benoit Pilmis, Vincent Jullien, Jack Sobel, Marc Lecuit, Olivier Lortholary, et al.. Antifungal drugs during pregnancy: an updated review. Journal of Antimicrobial Chemotherapy, 2014, 70 (1), pp.14-22. ⟨10.1093/jac/dku355⟩. ⟨pasteur-02454062⟩


44 View
0 Download



Gmail Mastodon Facebook X LinkedIn More